Rice Hall James & Associates LLC Takes Position in Evolus, Inc. $EOLS

Rice Hall James & Associates LLC purchased a new position in Evolus, Inc. (NASDAQ:EOLS) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 1,289,888 shares of the company’s stock, valued at approximately $8,952,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. OneDigital Investment Advisors LLC bought a new position in shares of Evolus in the 2nd quarter worth $104,000. Global Retirement Partners LLC purchased a new stake in shares of Evolus during the 2nd quarter worth $251,000. Bank of New York Mellon Corp bought a new stake in Evolus during the second quarter valued at about $1,130,000. State of Wyoming bought a new position in Evolus in the second quarter worth about $271,000. Finally, Assenagon Asset Management S.A. raised its holdings in Evolus by 51.8% in the second quarter. Assenagon Asset Management S.A. now owns 908,180 shares of the company’s stock worth $6,303,000 after purchasing an additional 310,035 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several analyst reports. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Finally, Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.50.

Evolus Stock Performance

Evolus stock opened at $7.77 on Tuesday. The stock has a market cap of $513.21 million, a PE ratio of -14.94 and a beta of 1.35. The stock has a 50-day moving average of $6.69 and a two-hundred day moving average of $5.67. Evolus, Inc. has a one year low of $3.86 and a one year high of $8.43.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.